**ImmunityBio, Inc. (IBRX) has reported mixed Q1 2026 earnings**, posting a loss of $0.09 per share compared to the expected loss of $0.08, while revenue reached $44.2 million, exceeding estimates of $41.1 million. The stock, trading at $7.72 as of May 28, 2026, has surged 289.9% year-to-date, with a projected 6-12 month price target of $8.25. The revenue growth reflects strong demand for its product, Anktiva, which has seen a 168% year-over-year increase.
**The company’s operating expenses have risen**, with R&D costs increasing to $68 million from $48.2 million year-over-year. Selling, general, and administrative expenses also grew to $45.8 million from $32.7 million, reflecting the investment needed for scaling its operations. ImmunityBio ended March 2026 with approximately $381 million in cash and $678 million in total debt.
**Going forward, ImmunityBio is focused on sustaining demand** amidst rising expenses and reliance on a single product. The company is driving efforts for international market expansion but faces potential slowdowns due to reimbursement processes in Europe, with Germany expected to lead commercialization efforts in 2026.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
